Ce site utilise des cookies dans le but de vous fournir un service plus réactif et personnalisé. Merci de bien vouloir lire la notice d'information sur les cookies et comment les effacer et les bloquer.

Enregistrer dans les favoris E-mail Imprimer cette page

    Plus

    Page   1/2   
  • Measuring the return from pharmaceutical innovation 2013
    For the last four years Deloitte and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines.
  • Impact of European Austerity on Pharmaceutical policy and pricing
    A UK Deloitte Centre for Health solutions report that looks to understand the current European pharmaceutical market, the mechanisms for reducing pharmaceutical spending, the future of the pharmaceutical landscape, and the actions the pharmaceutical industry needs to take to survive current austerity.
  • Measuring the return from pharmaceutical innovation 2012
    For the last three years, Deloitte LLP and Thomson Reuters have analysed the performance of the top 12 life sciences companies by estimating the projected financial returns from the investment in their late stage pipelines.
  • State of the Swiss Medical Technology Industry 2011
    Today’s economy exposes any marginal innovation, compliance and quality gaps faster globally, thus influencing performance of companies.
  • Sondage 2011 des consommateurs de santé en Suisse
    72 % se restreignent dans leurs dépenses de nécessité quotidienne (alimentation, formation, logement) au profit de leurs dépenses mensuelles de santé.
  • R&D value measurement
    Deloitte and Thomson Reuters have collaborated in this study of R&D value measurement, combining Deloitte’s R&D advisory experience and financial expertise with Thomson Reuters R&D data and business insights.
  • The Swiss Medical Technology Industry 2010 Survey
    After several years of continuous economic growth in Switzerland and abroad the Swiss Medtech industry is entering a new phase therefore being obliged to rethink strategic priorities.
  • Aftermath of the Global Recession
    New report explores current thinking among life sciences executives on how the global financial and economic crisis affected their business priorities and strategies.
  • Global Health Care Consumer Survey
    Learn more about the similarities and intriguing differences in health care behaviors and attitudes among consumers in the U.S., U.K, Canada, France, Germany and Switzerland.
  • Internal Audit in the pharmaceutical industry
    Deloitte Enterprise Risk Services in EMEA hosted the second European round table on the role of internal audit in the pharmaceutical industry on 20-21 October 2009 in Basel, Switzerland.
  • Page   1/2   
Restez connectés
Nous contacter